Chardan Capital maintains Buy rating on Agenus, $40 price target

Agenus Inc. (AGEN) reported 48% estimated three-year survival in recurrent ovarian cancer patients treated with BOT+BAL in its Phase 1b trial. Results showed durable benefit in heavily pretreated patients, with 25% alive and off therapy. The study was presented at the 2026 IGCS Annual Meeting.

Agenus reported 48% three-year overall survival in 35 patients from its Phase 1b ovarian cancer trial using botensilimab plus balstilimab. 25% of 44 treated patients were alive and off therapy at last follow-up. The results extend earlier Phase 1b signals, suggesting durability for the combination.

Chardan Capital initiated coverage of Agenus (AGEN) with a Buy rating and $40 price target, implying 454% upside from the Sep 17 close of $7.22. The firm highlights strong clinical data for Agenus's immunotherapy candidates, BOT and BAL, in treating MSS colorectal cancer, and the company's strategic focus on an unmet medical need.

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer • Previously announced oversubscribed $85 million private placement, with up to $255 million in potential proceeds from milestone-aligned

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.

Agenus Inc. (NASDAQ:AGEN) shares fell Tuesday after a record Monday surge of about 95% to 111% amid profit-taking. On Monday, the company reported Phase 1b data for botensilimab plus balstilimab in refractory MSS metastatic colorectal cancer, with median OS 21.2 months. Agenus also announced an $85M private placement plus up to $255M in warrants to fund its Phase 3 ROBBIN trial and shift from BATTMAN. HC Wainwright raised its AGEN price target to $30.